Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
1. In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher ...
Tag: T2DM
Diabetic polyneuropathy observed to have dynamic changes overtime
1. Neuropathic pain in diabetic polyneuropathy is dynamic over time, with distinct clinical and sensory predictors associated with both its ...
#VisualAbstract: Automated Insulin Delivery Effectively Reduces Blood Glucose Levels in Type 2 Diabetes
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Insulin Efsitora is Noninferior to Degludec in Type 2 Diabetes without Previous Insulin Treatment
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract Glucagon-Like Peptide-1 Receptor Agonists are Protecting in Type 2 Diabetes Mellitus Patients
Click here to read this article in JAMA Internal Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
High-dose oral semaglutide effectively glycemic control in patients with type 2 diabetes mellitus
1. HbA1c reduction was dose-dependent in the semaglutide group with the greatest change among patients on semaglutide 50 mg. 2. ...
Once-weekly tirzepatide significantly improves weight and glycemic control in patients with with obesity and type 2 diabetes
1. Body weight reduction at week 72 was significantly greater with tirzepatide versus placebo. 2. Hemoglobin A1c was significantly reduced ...
Retatrutide associated with improved glycemic control and bodyweight reduction in type 2 diabetes
1. HbA1c and bodyweight reduction were greater in the retatrutide group compared to dulaglutide and placebo. 2. The effect of ...
Orforglipron may be a safe and effective oral GLP-1 agonist for treatment of type 2 diabetes
1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body weight compared to other groups. 2. The majority ...
Once-weekly insulin icodec non-inferior to daily insulin glargine for patients with type 2 diabetes on basal-bolus regimens
1. At 26 weeks, the mean change in HbA1c was comparable between the weekly insulin icodec and daily glargine U100 ...
